GlaxoSmithKline News and Research

RSS

First Edition: December 17, 2013

Today's headlines include reports about how the health law is viewed by immigrant populations.

17 Dec 2013

Research findings point to possible new strategy for treating ALS

Amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is a devastating illness that gradually robs sufferers of muscle strength and eventually causes a lethal, full-body paralysis. The only drug available to treat the disease extends life spans by a meager three months on average.

17 Dec 2013

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.

12 Dec 2013

Medicines for rare diseases may be effectively valued using multi-criteria decision analysis

A study just published by the Office of Health Economics and its collaborators demonstrates how medicines for rare disease may be effectively valued using an innovative approach -- multi-criteria decision analysis -- that can include all relevant stakeholders, including patients' groups.

5 Dec 2013

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.

27 Nov 2013

GSK and Save the Children to help roll out student-created breathing technology in Africa

A low-cost device that Rice University bioengineering students invented to help premature babies breathe more easily will be rolled out to teaching hospitals in three African nations, thanks to a $400,000 award from pharmaceutical giant GlaxoSmithKline and London-based charity Save the Children. The technology, which is known as "bubble CPAP," earned the top prize in GSK and Save the Children's inaugural Healthcare Innovation Award program.

15 Nov 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.

15 Nov 2013

Inhibition of heart protein reduces damage from heart attack, say researchers

The stop and start of blood flow to the heart during and after a heart attack causes severe damage to heart cells, reducing their capacity to function and potentially causing their death.

7 Nov 2013

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.

1 Nov 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

Pertussis incidence: an interview with Leonard Friedland, M.D., V.P. and Director of Scientific Affairs and Public Health for GSK Vaccines

Distinguishing pertussis (also known as whooping cough) from other respiratory illnesses is challenging in particular among adults because the signs and symptoms of pertussis overlap with those of other respiratory diseases.

24 Oct 2013

Parental perceptions pose major barrier to acceptance of HPV vaccination

A Mayo Clinic physician and two other pediatric experts say that parental perceptions pose a major barrier to acceptance of human papillomavirus (HPV) vaccination — and that many of those perceptions are wrong.

22 Oct 2013

New article in Preventive Medicine journal explores suspicions about sexual promiscuity, vaccine safety

Suspicions about sexual promiscuity and vaccine safety are explored in an article in the November issue of the journal Preventive Medicine, which dedicates a section of that issue to research concerning the human papillomavirus.

18 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Eddingpharm Secures Immutep’s Immufact IMP321 For Growing Stable

Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan.

7 Oct 2013

GSK Adds Another Program To Isis Antisense Collab

...

7 Oct 2013

GSK Sells Thrombosis Brands To Aspen For $1.13B

...

30 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

JPM, Bill & Melinda Gates Foundation announces capital raise for first-of-its-kind investment product

A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.